PR Newswire PharmaOriginal article
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II
RegulatoryBlue Light Cystoscopy SystemsPositive
AI Analysis
Summary
Photocure announced that the FDA published a proposed order to reclassify its blue light cystoscopy systems from Class III to Class II medical devices. This regulatory reclassification could streamline the approval pathway for the company's bladder cancer diagnostic technology.
Outcome Details
FDA published proposed order to initiate reclassification from Class III to Class II
Importance:7/10
Sentiment:
0.70
FDAreclassificationcystoscopybladder cancerregulatory
Related Companies
Read the original article
Published by PR Newswire Pharma on August 14, 2026 4:18 PM